Intraday Movement and Market Context
On 17 Dec 2025, Concord Biotech’s stock price touched an intraday low of Rs.1325, representing a decline of 3.93% on the day. This movement was sharper than the sector’s performance, with the stock underperforming the Pharmaceuticals & Biotechnology sector by 3.95%. The broader market, represented by the Sensex, opened positively with a gain of 176.40 points but later reversed to close 296.61 points lower at 84,559.65, down 0.14%. Despite the Sensex trading near its 52-week high and above key moving averages, Concord Biotech’s shares remained below all major moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
Long-Term Price Performance
Over the past year, Concord Biotech’s stock has recorded a return of -35.21%, contrasting with the Sensex’s positive return of 4.80% during the same period. The stock’s 52-week high was Rs.2451.65, indicating that the current price level is nearly 46% lower than its peak within the last year. This extended period of price decline highlights the challenges faced by the company in maintaining investor confidence and market valuation.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Financial Metrics Reflecting Recent Performance
Concord Biotech’s financial data over recent quarters and years reveals several factors contributing to the current stock price level. The company’s operating profit has shown a compound annual rate of change of -0.48% over the last five years, indicating subdued growth in core earnings. The latest quarterly Profit Before Tax (PBT) stood at Rs.72.33 crores, which is 32.1% lower than the average of the previous four quarters. Operating cash flow for the year was recorded at Rs.244.52 crores, marking the lowest level in recent periods. Additionally, the Profit After Tax (PAT) for the latest six months was Rs.107.64 crores, reflecting a decline of 30.70% compared to prior periods.
Valuation and Efficiency Indicators
Despite the recent price decline, Concord Biotech’s return on equity (ROE) remains relatively high at 17.7%, suggesting efficient utilisation of shareholder funds. However, the stock’s price-to-book value ratio stands at 7.8, indicating a valuation considered expensive relative to book value. When compared to its peers, the stock trades at a valuation level that aligns with historical averages within the Pharmaceuticals & Biotechnology sector. The company’s debt-to-equity ratio averages at zero, reflecting a low leverage position and a conservative capital structure.
Comparative Sector and Market Performance
Concord Biotech’s performance over the last three years, one year, and three months has been below that of the BSE500 index, highlighting a trend of underperformance relative to a broad market benchmark. While the Sensex remains in a bullish phase, trading above its 50-day and 200-day moving averages, Concord Biotech’s shares have not mirrored this positive momentum. The divergence between the stock’s trajectory and the broader market indices underscores the specific challenges faced by the company within its sector.
Holding Concord Biotech from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Shareholding and Management Overview
The majority of Concord Biotech’s shares are held by promoters, indicating a concentrated ownership structure. The company’s management efficiency is reflected in its relatively high ROE of 19.17%, which suggests effective utilisation of equity capital. The absence of debt in the capital structure further points to a cautious financial approach, reducing exposure to interest obligations and financial risk.
Summary of Key Price and Performance Indicators
To summarise, Concord Biotech’s stock has reached a new 52-week low of Rs.1325, down from a high of Rs.2451.65 within the last year. The stock’s one-year return of -35.21% contrasts with the Sensex’s positive 4.80% return, highlighting a significant divergence. Financial results show declines in profit before tax and profit after tax in recent periods, alongside subdued operating cash flow. Valuation metrics indicate a relatively high price-to-book ratio despite the price fall, while the company maintains a low debt profile and strong management efficiency.
Market and Sector Outlook Context
While the broader market indices such as the Sensex continue to trade near their 52-week highs and maintain bullish moving averages, Concord Biotech’s share price remains under pressure. The Pharmaceuticals & Biotechnology sector has experienced mixed performance, with Concord Biotech’s stock lagging behind sector averages. This divergence reflects company-specific factors influencing investor sentiment and market valuation.
Conclusion
Concord Biotech’s fall to its 52-week low of Rs.1325 marks a notable point in its recent market journey. The stock’s performance over the past year and recent financial data illustrate a period of subdued growth and valuation pressures. While the company maintains strong management efficiency and a conservative capital structure, the current price level reflects the market’s assessment of its recent financial trends and sectoral dynamics.
Only for Rs. 14,999 - Get Access to 2 Years + 6 Months of All Premium Features on MarketsMojo. As low as ₹500/month! Claim 83% OFF →
